ABSCIENCES (EPA:AB) | Finanzwire

Basculer en Français

8596	Companies
140108	Keywords
76032	Articles
74810	Press releases

Home
Companies
ABSCIENCES

BRIEF

published on 03/04/2025 at 08:40, 30 days ago

Masitinib Emerges as Potential Game-Changer in MS Treatment

AB Science Masitinib Neuroinflammation Progressive MS Patrick Vermersch
PRESS RELEASE

published on 03/04/2025 at 08:35, 30 days ago

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
AB Science's masitinib and its phase 3 principal investigator, neurologist Patrick Vermersch, featured in Life Sciences Magazine for potential breakthrough in Progressive MS Treatment

AB Science Masitinib Patrick Vermersch Life Sciences Magazine Progressive MS Treatment
BRIEF

published on 01/29/2025 at 19:08, 2 months 4 days ago

AB Science Updates on Masitinib Platform Progress

Multiple Sclerosis Masitinib Platform ALS Study Alzheimer’s Treatment AB Science Strategy
PRESS RELEASE

published on 01/29/2025 at 19:03, 2 months 4 days ago

AB Science today provides an update on its masitinib platform
AB Science provides update on masitinib platform for ALS, MS, and AD. Positive results show potential for huge market sales. Debt negotiation planned

Update AB Science Masitinib Platform Market Sales Debt Negotiation
BRIEF

published on 01/24/2025 at 18:06, 2 months 9 days ago

AB Science to Present Masitinib Update in Upcoming Webcast

Pharmaceuticals Webcast Research Update AB Science Masitinib
PRESS RELEASE

published on 01/24/2025 at 18:01, 2 months 9 days ago

AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
AB Science to host live webcast on masitinib platform update on January 28, 2025, 5.30pm CET. Leading pharmaceutical company specializing in protein kinase inhibitors

Pharmaceutical Company Live Webcast AB Science Protein Kinase Inhibitors Masitinib Platform
BRIEF

published on 01/22/2025 at 19:04, 2 months 11 days ago

AB Science Participates in Biomed Forum Investors Conference

Investor Conference BIOMED Forum AB Science Masitinib Protein Kinase Inhibitors
PRESS RELEASE

published on 01/22/2025 at 18:59, 2 months 11 days ago

AB Science will participate in the Biomed Forum investors conference
AB Science to participate in Biomed Forum Investors Conference organized by AllInvest Securities in Paris on February 4, 2025

Pharmaceutical Company BIOMED Forum AB Science Investors Conference AllInvest Securities
BRIEF

published on 12/17/2024 at 19:09, 3 months 16 days ago

AB Science presents the advances of AB8939 for acute myeloid leukemia

Phase 1 AB8939 Acute Myeloid Leukemia Drug Resistance Potential Market
PRESS RELEASE

published on 12/17/2024 at 19:04, 3 months 16 days ago

AB Science provides a summary of the webcast held on December 16, 2024
AB Science provides an update on AB8939, a novel microtubule destabilizer and ALDH inhibitor in phase 1 for AML treatment. Potential market size exceeded EUR 2 billion per annum

Market Potential AML Treatment AB Science Phase 1 AB8939

Accesswire

Published on 04/03/2025 at 05:10, 3 hours 52 minutes ago

Battery X Metals Announces Corporate Awareness Agreement
Published on 04/03/2025 at 01:35, 7 hours 27 minutes ago

GMV Minerals Inc. Closes Non-Brokered Financing/ Engages Investor Relations Firm
Published on 04/02/2025 at 23:35, 9 hours 27 minutes ago

Murchison Minerals to Seek Shareholders’ Approval for Share Consolidation
Published on 04/02/2025 at 20:00, 13 hours 2 minutes ago

Network-1 Announces Acquisition of Patent Portfolio
Published on 04/02/2025 at 17:25, 15 hours 37 minutes ago

SOBRsafe Announces Reverse Stock Split

View all ACCESSWIRE

EQS Group

Published on 04/03/2025 at 08:30, 32 minutes ago

ALVAREZ & MARSAL CREATES LEADING CORPORATE FINANCE PRACTICE IN SWITZERLAND BY JOINING FORCES WITH AVELA CAPITAL LED BY STEPHAN BRÜCHER
Published on 04/03/2025 at 08:15, 47 minutes ago

'CGTN: China-India ties at 75: 'Dragon-Elephant Tango' will benefit both'
Published on 04/03/2025 at 08:00, 1 hour 2 minutes ago

SWEF: Full Year Results for the Year Ended 31 December 2024
Published on 04/03/2025 at 08:00, 1 hour 2 minutes ago

Partnership with Claro: cyan AG advances into Latin American market and opens up new growth prospects
Published on 04/03/2025 at 08:00, 1 hour 2 minutes ago

Transaction in Own Shares

Les Echos

Published on 04/03/2025 at 08:45, 17 minutes ago

Baikowski: Strong growth in 2024 full-year results
Published on 04/03/2025 at 08:00, 1 hour 2 minutes ago

Availability of preparatory documents for the Annual Shareholders’ Meeting of OPmobility SE
Published on 04/03/2025 at 00:37, 8 hours 25 minutes ago

Publication of the report on payments made to governments provided by article L.225-102-3 of the French Commercial Code
Published on 04/02/2025 at 18:05, 14 hours 57 minutes ago

Financial statements - 31 december 2024
Published on 04/02/2025 at 17:45, 15 hours 17 minutes ago

Aéroports de Paris SA - Voting rights as of 31 March 2025

View all LES ECHOS COMFI WIRE